PARKINSONISM trends in the UK reveal falling PD incidence, rising prevalence, and increasing recognition of vascular Parkinsonism (VP).
Parkinsonism Trends Show Diverging Patterns
A large UK cohort study found that the epidemiology of Parkinsonism subtypes has shifted over time, with Parkinson’s disease showing a slight decline in incidence but a rise in prevalence, while vascular Parkinsonism (VP) became increasingly recorded and drug induced Parkinsonism remained largely stable. The analysis used routinely collected primary care data from 2007–2021 and included adults with at least 1 year of prior observation. Annual incidence and prevalence were assessed for Parkinson’s disease, VP, and drug induced Parkinsonism, with stratification by age and sex.
From 2007 to 2019, the age standardized incidence of Parkinson’s disease fell from 35.61 to 31.27 per 100,000 person years. Over a similar period, prevalence rose from 0.21% in 2007 and peaked at 0.23% in 2016. The authors suggested that this divergence between incidence and prevalence may reflect improved survival and care. By contrast, VP diagnoses increased from 2010 onward, while drug induced Parkinsonism showed relatively stable incidence and prevalence throughout the study period.
Parkinsonism Trends Varied by Age and Sex
The burden of Parkinsonism increased with age across subtypes, although the age effect was less marked for drug induced Parkinsonism. Parkinson’s disease and VP were generally more common in males, whereas drug induced Parkinsonism was slightly more common in females. The study also found that patients with VP had the highest median age at diagnosis, while those with drug induced Parkinsonism were younger on average.
Among adults older than 70 years, incidence patterns diverged further. Parkinson’s disease incidence decreased, whereas VP incidence increased. In prevalence analyses, Parkinson’s disease rose steadily in older age groups, while drug induced Parkinsonism remained stable. These findings suggest that clinicians may increasingly encounter a more heterogeneous Parkinsonism population in older adults, with important differences in sex distribution, comorbidity patterns, and likely drivers of disease.
Clinical Relevance for Practice
The study included 20,006 patients with Parkinson’s disease, 1,126 with VP, and 809 with drug induced Parkinsonism. Patients with VP were more likely to have chronic kidney disease, dementia, stroke, and cardiovascular disease, while those with drug induced Parkinsonism more often had anxiety, depression, and prior exposure to antidepressants, antiepileptics, and psycholeptics. The authors noted that rising VP rates may reflect improved diagnostic recognition, while stable drug induced Parkinsonism rates may indicate greater awareness of causative medications and earlier review of treatment histories.
The authors also highlighted important limitations, including possible misclassification between Parkinson’s disease, VP, and drug induced Parkinsonism, as well as under recording in primary care when diagnoses made in specialist settings are not promptly captured by general practitioners. Even so, the overall message is clear: as the population ages, Parkinsonism subtypes are likely to represent an increasing clinical burden, and subtype specific recognition will matter for screening, diagnosis, and care planning.
Reference
Chen X et al. Secular trends of incidence and prevalence of Parkinsonism subtypes: a cohort study in the United Kingdom. European Journal of Public Health. 2026;36(2):ckag031.
Featured Image: wavebreak3 on Adobe Stock.
